Related Experiment Video
Updated: Dec 12, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Pertussis Infections Among Pregnant Women in the United States, 2012-2017
Tami H Skoff1, Amanda E Faulkner1, Jennifer L Liang1
1Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Insights
Pertussis (whooping cough) incidence and symptoms are similar in pregnant and nonpregnant women. Continued surveillance is needed to understand pertussis epidemiology in pregnant individuals.
Area of Science:
- Public Health
- Epidemiology
- Infectious Diseases
Background:
- Pregnant women face increased risks for severe respiratory infections.
- Pertussis (whooping cough) epidemiology in pregnant women is not well understood.
Purpose of the Study:
- To describe pertussis epidemiology among pregnant and nonpregnant women of childbearing age.
- To compare disease characteristics and incidence between pregnant and nonpregnant women.
Main Methods:
- Utilized the Centers for Disease Control and Prevention's Enhanced Pertussis Surveillance (EPS) system.
- Analyzed pertussis cases in women aged 18-44 years from 2012-2017 in 7 EPS states.
- Collected data via patient/provider interviews and immunization registries; used population and birth data for incidence calculations.
Main Results:
- Identified 1582 pertussis cases; 5.1% of cases occurred in pregnant women, mostly in the second or third trimester.
- Incidence rates were similar: 7.7/100,000 for pregnant women vs. 70.3/100,000 for nonpregnant women.
- Clinical symptoms (whoop, posttussive vomiting, apnea) and Tdap vaccination rates were similar between pregnant and nonpregnant groups.
Conclusions:
- Pertussis incidence and clinical presentation appear similar between pregnant and nonpregnant women.
- Further ongoing surveillance is crucial for a comprehensive understanding of pertussis in pregnant populations.
Background:
Little is known about pertussis among pregnant women, a population at increased risk for severe morbidity from respiratory infections such as influenza. We used the Centers for Disease Control and Prevention's Enhanced Pertussis Surveillance (EPS) system to describe pertussis epidemiology among pregnant and nonpregnant women of childbearing age.
Methods:
Pertussis cases in women aged 18-44 years with cough onset between 1 January 2012 and 31 December 2017 were identified in 7 EPS states. Surveillance data were collected through patient and provider interviews and immunization registries. Bridged-race, intercensal population data and live birth estimates were used as denominators.
Results:
We identified 1582 pertussis cases among women aged 18-44 years; 5.1% (76/1499) of patients with a known pregnancy status were pregnant at cough onset. Of the pregnant patients with complete information, 81.7% (49/60) reported onset during the second or third trimester. The median ages of pregnant and nonpregnant patients were 29.0 and 33.0 years, respectively. Most pregnant and nonpregnant patients were White (78.3% vs. 86.4%, respectively; P = .09) and non-Hispanic (72.6% vs. 77.3%, respectively; P = .35). The average annual incidence of pertussis was 7.7/100000 among pregnancy women and 7/3/100000 among nonpregnant women. Compared to nonpregnant patients, more pregnant patients reported whoop (41.9% vs. 31.3%, respectively), posttussive vomiting (58.1% vs. 47.9%, respectively), and apnea (37.3% vs. 29.0%, respectively); however, these differences were not statistically significant (P values > .05 for all). A similar proportion of pregnant and nonpregnant patients reported ever having received Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; 31.6% vs. 32.7%, respectively; P = .84).
Conclusions:
Our analysis suggests that incidence of pertussis and clinical characteristics of disease are similar among pregnant and nonpregnant women. Continued monitoring is important to further define pertussis epidemiology in pregnant women.
More Related Videos
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Vaccinations
Sexually Transmitted Infections
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

